Lewis M G
Hautarzt. 1978 Dec;29(12):619-24.
The immune response of malignant melanoma bases on evident humoral and cellular defence mechanisms of the host against his tumor. Of special interest is a defective immune response, developing in the course of the disease. Hence, any immunotherapy aims at an immunostimulation and immunoregulation. Local and systemic nonspecific immunotherapy try to raise an immune response against the tumor by stimulating unspecifically the whole immune system. On the contrary, specific immunotherapy tries to stimulate directly the defence mechanisms against the tumor by transfusion of antisera (passive immunotherapy) and sensitized cells (adoptive immunotherapy) and by immunizing the patient with tumor tissue (active immunotherapy). One of the best ways in therapy of melanoma seems to be the combination of immunotherapy with chemotherapy, as yet employed in BCG and DTIC treatment.
恶性黑色素瘤的免疫反应基于宿主针对其肿瘤的明显体液和细胞防御机制。特别值得关注的是在疾病过程中出现的免疫反应缺陷。因此,任何免疫疗法都旨在进行免疫刺激和免疫调节。局部和全身非特异性免疫疗法试图通过非特异性刺激整个免疫系统来引发针对肿瘤的免疫反应。相反,特异性免疫疗法试图通过输注抗血清(被动免疫疗法)和致敏细胞(过继免疫疗法)以及用肿瘤组织对患者进行免疫(主动免疫疗法)来直接刺激针对肿瘤的防御机制。黑色素瘤治疗的最佳方法之一似乎是免疫疗法与化疗相结合,目前在卡介苗和氮烯咪胺治疗中已经采用了这种方法。